

Robert Greene Stone  
Edward J. Kessler  
Jorge A. Goldstein  
David K.S. Cornwell  
Robert W. Esmond  
Tracy-Gene G. Durkin  
Michael A. Cimbal  
Michael B. Day  
Robert E. Sokohl  
Eric K. Staffo  
Michael Q. Lee  
Steven R. Ludwig  
John M. Covert  
Linda E. Alcorn  
Robert C. Millenig  
Lawrence B. Bugelsky  
Donald J. Featherstone  
Michael V. Messinger

Josh U. Kim  
Timothy J. Shea, Jr.  
Patrick E. Geretti  
Jeffrey T. McVey  
Heidi L. Kraus  
Albert L. Ferro  
Donald R. Benowitz  
Peter A. Jackson  
Teresa U. Medler  
Jeffrey S. Weaver  
Kendrick P. Patterson  
Vincent L. Caputo  
Edna Ellen Floyd  
Thomas C. Fiala  
Brian J. Del Buono  
Virgil Lee Beason  
Theodore A. Wood  
Elizabeth J. Haenes

Joseph S. Ostroff  
Frank R. Cunningham  
Christina M. Unluer  
Rea Lynn P. Guest  
George S. Bardmesser  
Daniel A. Klein  
Jason D. Eisenberg  
Michael D. Specht  
Andrea J. Kamaga  
Tracy L. Muller  
Jon E. Wright  
LuAnne M. DeSantis  
Ann E. Summerfield  
Aric W. Ledford  
Helene C. Carlson  
Timothy A. Doyle  
Geby L. Longworth  
Lari A. Gordon

Nicole D. Dreier  
Ted J. Ebersole  
Jared C. Iyer  
Laura A. Vogel  
Michael J. Mancuso  
Registered Patent Agents  
Karen R. Markowicz  
Nancy J. Leish  
Matthew J. David  
Aaron L. Schwartz  
Kathryn Yulian Pol Quech  
Ryan L. Seaton  
Robert A. Schwartzman  
Teresa A. Catella  
Jeffrey S. Lundgren  
Victoria S. Rutherford  
Michelle K. Holoubek

Robert H. DeSalvo  
Simon J. Elbert  
Julia A. Heller  
Mita Mukherjee  
Scott M. Woodhouse  
Michael G. Penn  
Christopher J. Walsh

Of Counsel  
Kenneth C. Bass II  
Evan R. Smith  
Mervin C. Guthrie

\*Admitted only in Maryland  
\*Admitted only in Virginia  
•Practice Limited to  
Federal Agencies

December 17, 2004

WRITER'S DIRECT NUMBER:  
(202) 772-8637  
INTERNET ADDRESS:  
KAREN@SKGF.COM

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**Mail Stop Amendment**

**Art Unit: 1645**

Re: U.S. Utility Patent Application  
Application No. 10/623,813; Filed: July 22, 2003  
For: **De novo DNA Cytosine Methyltransferase  
Genes, Polypeptides and Uses Thereof**  
Inventors: LI *et al.*  
Our Ref: 0609.4560003/KRM/DJN

Sir:

Transmitted herewith for appropriate action are the following documents:


1. First Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b);
2. One page of Form PTO-1449 citing two documents AR20-AS20;
3. Copies of the documents as listed on Form PTO-1449; and
4. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

  
Karen R. Markowicz  
Agent for Applicants  
Registration No. 36,351

KRM/DJN:dbj  
Enclosures

345522\_1.DOC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re application of:

Li *et al.*

Appl. No.: 10/623,813

Filed: July 22, 2003

For: ***De novo* DNA Cytosine**

**Methyltransferase Genes,**

**Polypeptides and Uses Thereof**

Confirmation No.: 2332

Art Unit: 1645

Examiner: *To be assigned*

Atty. Docket: 0609.4560003/KRM/DJN

**First Supplemental Information Disclosure Statement  
Under 37 C.F.R. § 1.97(b)**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed on January 20, 2004 in connection with the above-captioned application. A copy of each document is provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Karen R. Markowicz  
Agent for Applicants  
Registration No. 36,351

Date:

12.17.04

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

FORM PTO-1449

ATTY. DOCKET NO.  
0609.4560003/KRM/DJNAPPLICATION NO.  
10/623,813FIRST NAMED INVENTOR  
Li *et al.*FILING DATE  
July 22, 2003ART UNIT  
1645FIRST SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>20</u>	Okano, M., <i>et al.</i> , "Dnmt2 is not required for <i>de novo</i> and maintenance methylation of viral DNA in embryonic stem cells," <i>Nucl. Acids Res.</i> 26:2536-2540, Oxford University Press (June 1998)
	AS	<u>20</u>	Pradhan, S., <i>et al.</i> , "Baculovirus-mediated expression and characterization of the full-length murine DNA methyltransferase," <i>Nucl. Acids Res.</i> 25:4666-4673, Oxford University Press (November 1997)
	AT		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.